A big downfall in the stock market is brewing and investors aren't noticing, according to strategists at investment bank Societe Generale. » Read More
In an exclusive interview with CNBC, the legendary Vanguard founder forecasts what's next for the global investment market. » Read More
By: Tae Kim
Nomura Instinet reiterates its buy rating for Amazon shares, saying it will dominate due to its ability to invest aggressively. » Read More
By: Michael Sheetz
Some of the names on the move ahead of the open. » Read More
Jim Cramer exposes the good, bad and ugly when dealing with 401(k) and IRA contributions. Roth or no Roth? That is the question.
Jim Cramer says students who graduate with no debt end up being worth more than classmates with outstanding loans.
Jim Cramer explains key money-managing strategies that young investors probably won't learn in school.
Investors are ditching insurance stocks as Irma pounds the Caribbean, even though industry leaders say companies can handle the impact.
Jim Cramer explains how his view of the market was forever rocked by the 2008 recession.
Jim Cramer opens up about mistakes of investing, and his rules for owning individual stocks.
Jim Cramer shares the story of how he learned to get an edge on the market.
Jim Cramer explains what it means to own a best-of-breed stock.
Goldman Sachs says the division between the chaos in Washington and the relative calm outside the Beltway is confusing investors.
Goldman Sachs shares with clients its top global e-commerce stock picks.
The insurance industry has about $700 billion in surplus ready to pay claims, Insurance Information Institute CEO Sean Kevelighan told CNBC.
Continued shutdowns of "nearly all of Newell Brands' resin suppliers" in the two states are unexpectedly driving up resin costs.
Securities transactions must now settle within two business days instead of three.
Early retirees and super-savers share their top tips for saving big.
The "Fast Money" traders share their first moves for the market open.
Some of the names on the move ahead of the open.
Sarepta Therapeutics reports positive results from a clinical trial of an experimental medicine for Duchenne muscular dystrophy.
Investors simply need to adjust to the current environment rather than ditch their equity portfolios amid geopolitical concerns and fears of a market correction, a U.S. asset manager told CNBC Wednesday.
Small-cap stocks may have run too high in too short a time, says one trader.
Jim Cramer says S&P 500 futures, not stocks themselves, are the biggest determinant for market-wide sell-offs.
Get the best of CNBC in your inbox